ATNF News

Yahoo! Finance Aug 10, 2023 08:46 AM ET

180 Life Sciences Corp. Announces Pricing of $3 Million Public Offering

ATNF $1.72 (0.00%)

Yahoo! Finance Aug 07, 2023 09:00 AM ET

180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake

ATNF $1.72 (0.00%)

Yahoo! Finance Aug 03, 2023 08:00 AM ET

180 Life Sciences Provides Update on Regulatory Approval Process in the UK and US for Dupuytren’s Disease Treatment; Continues Consultations with the UK MHRA and Initiates a Type C Meeting Request With the US FDA

ATNF $1.72 (0.00%)

Yahoo! Finance Jul 31, 2023 08:00 AM ET

180 Life Sciences Corp. Announces the Filing of a Provisional Patent Describing the Combination of CBD With GLP-1 Agonists to Suppress Appetite

ATNF $1.72 (0.00%)

Yahoo! Finance Apr 10, 2023 04:30 PM ET

180 Life Sciences Corp. Announces Closing of $3 Million Registered Direct Offering and Concurrent Private Placement

ATNF $1.72 (0.00%)

Yahoo! Finance Apr 05, 2023 01:00 PM ET

180 Life Sciences Corp. Announces $3 Million Registered Direct Offering and Concurrent Private Placement

ATNF $1.72 (0.00%)

Yahoo! Finance Feb 27, 2023 08:30 AM ET

180 Life Sciences Announces Presentation at the Gordon Conference

ATNF $1.72 (0.00%)

Yahoo! Finance Jan 25, 2023 08:45 AM ET

180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytren’s Disease

ATNF $1.72 (0.00%)

Yahoo! Finance Jan 17, 2023 08:00 AM ET

180 Life Sciences Engages Kinexum for Assistance in Applying for Marketing Authorisation in the United Kingdom

ATNF $1.72 (0.00%)

Yahoo! Finance Jan 05, 2023 08:30 AM ET

180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement

ATNF $1.72 (0.00%)

Yahoo! Finance Jan 04, 2023 08:30 AM ET

180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytren’s Disease

ATNF $1.72 (0.00%)

Yahoo! Finance Dec 29, 2022 08:30 AM ET

180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders

ATNF $1.72 (0.00%)

Yahoo! Finance Dec 23, 2022 08:00 AM ET

180 Life Sciences Corp. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

ATNF $1.72 (0.00%)

Yahoo! Finance Dec 20, 2022 02:11 PM ET

180 Life Sciences Corp. Announces $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

ATNF $1.72 (0.00%)

Yahoo! Finance Dec 16, 2022 09:00 AM ET

180 Life Sciences Corp. Announces 1-for 20 Reverse Stock Split as Part of Nasdaq Compliance Plan

ATNF $1.72 (0.00%)

Yahoo! Finance Nov 30, 2022 05:00 PM ET

180 Life Sciences Provides Update on Progress To Seek Medicines and Healthcare Products Regulatory Agency Marketing Authorization for Anti-TNF Treatment of Early Stage Dupuytren’s Contracture

ATNF $1.72 (0.00%)

Yahoo! Finance Nov 21, 2022 08:30 AM ET

180 Life Sciences to Participate in A.G.P.’s Virtual Biotech Conference to be Held November 30 – December 1, 2022

ATNF $1.72 (0.00%)

Yahoo! Finance Nov 15, 2022 12:37 PM ET

CORRECTION: Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren’s Disease

ATNF $1.72 (0.00%)

Yahoo! Finance Nov 15, 2022 08:00 AM ET

Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren’s Disease

ATNF $1.72 (0.00%)

Yahoo! Finance Sep 26, 2022 08:30 AM ET

180 Life Sciences Issues Letter to Stockholders

ATNF $1.72 (0.00%)

Yahoo! Finance Aug 22, 2022 08:30 AM ET

180 Life Sciences with the University of Oxford Announce the Enrollment of the First Patient in a Trial of Anti-TNF for People with Early-Stage Frozen Shoulder

ATNF $1.72 (0.00%)

Yahoo! Finance Jul 27, 2022 08:30 AM ET

180 Life Sciences Announces That the University of Oxford Has Been Awarded a Grant From the National Institute for Health and Care Research in the U.K. to Conduct a Clinical Trial in Post Operative Delirium/Cognitive Deficit in a Jointly Funded Program With 180 Life Sciences Corp.

ATNF $1.72 (0.00%)

Yahoo! Finance Jul 21, 2022 08:00 AM ET

180 Life Sciences Corp. Announces Closing of $6.5 Million Registered Direct Offering

ATNF $1.72 (0.00%)

Yahoo! Finance Jul 18, 2022 08:30 AM ET

180 Life Sciences Corp. Announces $6.5 Million Registered Direct Offering

ATNF $1.72 (0.00%)

Yahoo! Finance Jun 22, 2022 04:05 PM ET

180 Life Sciences Corp. Issues Letter to Stockholders

ATNF $1.72 (0.00%)

Yahoo! Finance Jun 14, 2022 04:15 PM ET

180 Life Sciences Provides Update on Correspondence Received from U.K. and U.S. Regulatory Authorities on Pathway for a Therapy That Could Prevent Progression of Early-Stage Dupuytren’s Disease

ATNF $1.72 (0.00%)

Yahoo! Finance May 31, 2022 08:30 AM ET

180 Life Sciences Begins Consultations with UK and US Regulatory Authorities on Pathway for a Therapy that Could Prevent Progression of Early-Stage Dupuytren’s Disease

ATNF $1.72 (0.00%)

Yahoo! Finance May 02, 2022 08:00 AM ET

REPEAT - 180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren’s Disease Study Results in The Lancet Rheumatology

ATNF $1.72 (0.00%)

Yahoo! Finance Apr 29, 2022 06:32 PM ET

180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren’s Disease Study Results in The Lancet Rheumatology

ATNF $1.72 (0.00%)

Yahoo! Finance Feb 17, 2022 08:30 AM ET

180 Life Sciences Corp. Forms Scientific Advisory Board

ATNF $1.72 (0.00%)

Yahoo! Finance Jan 31, 2022 08:00 AM ET

180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders

ATNF $1.72 (0.00%)

Yahoo! Finance Dec 28, 2021 11:00 AM ET

180 Life Sciences Corp. To Participate in the Biotech Showcase 2022 Virtual Conference To be Held January 10-12, 2022

ATNF $1.72 (0.00%)

Yahoo! Finance Dec 15, 2021 08:15 AM ET

180 Life Sciences Corp. Enters into a License Agreement with University of Oxford for Regenerative Molecule HMGB1 for Liver Diseases

ATNF $1.72 (0.00%)

Yahoo! Finance Dec 12, 2021 06:06 AM ET

Insider Buying: The 180 Life Sciences Corp. (NASDAQ:ATNF) Lead Independent Director Just Bought 328% More Shares

ATNF $1.72 (0.00%)

Yahoo! Finance Dec 10, 2021 05:15 PM ET

180 Life Sciences Corp (ATNF) CEO James N. Woody Bought $53,375 of Shares

ATNF $1.72 (0.00%)

Yahoo! Finance Dec 06, 2021 08:15 AM ET

180 Life Sciences Provides Follow-Up Information on Oxford University and the Company’s Successful Dupuytren’s Phase 2b Clinical Trial Results

ATNF $1.72 (0.00%)

Yahoo! Finance Dec 01, 2021 02:45 PM ET

180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal Presents Keynote Address at the 2021 International Dupuytren Symposium, Including Top Line Data From the Phase 2b Clinical Trial

ATNF $1.72 (0.00%)

Yahoo! Finance Dec 01, 2021 02:26 PM ET

180 Life Sciences: Positive Data From Dupuytren’s Disease Study Could Be a Big Catalyst, Says Analyst

ATNF $1.72 (0.00%)

Yahoo! Finance Nov 22, 2021 08:30 AM ET

180 Life Sciences Corp. Expands Patent Portfolio

ATNF $1.72 (0.00%)

Yahoo! Finance Nov 18, 2021 08:15 AM ET

180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal to Present a Keynote Address at the 2021 International Dupuytren Symposium

ATNF $1.72 (0.00%)

Yahoo! Finance Nov 03, 2021 12:06 PM ET

180 Life Sciences Corp. Names Quan A. Vu Chief Operating Officer/Chief Business Officer

ATNF $1.72 (0.00%)

Yahoo! Finance Oct 26, 2021 08:30 AM ET

180 Life Sciences Corp. Publishes Pre-Clinical Study Report on the Effects of CBG Derivatives on Pain, Inflammation and Obesity in The Journal Molecules

ATNF $1.72 (0.00%)

Yahoo! Finance Sep 30, 2021 08:30 AM ET

180 Life Sciences Corp. Continues To Expand Intellectual Property Portfolio

ATNF $1.72 (0.00%)

Yahoo! Finance Sep 20, 2021 08:00 AM ET

Celltrion Healthcare and 180 Life Sciences Enter Into Memorandum of Understanding for a Supply Agreement for the Ongoing Supply of Drug for Anti-TNF Product Trials for Novel Indications

ATNF $1.72 (0.00%)

Yahoo! Finance Aug 30, 2021 08:30 AM ET

180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders

ATNF $1.72 (0.00%)

Yahoo! Finance Aug 24, 2021 08:30 AM ET

180 Life Sciences Corp. Announces Closing of $15.0 Million Private Placement

ATNF $1.72 (0.00%)

Yahoo! Finance Aug 19, 2021 09:00 AM ET

180 Life Sciences Corp. Announces $15.0 Million Private Placement

ATNF $1.72 (0.00%)

Yahoo! Finance Aug 02, 2021 08:00 AM ET

Chairman of the 180 Life Sciences Clinical Advisory Board, Professor Jagdeep Nanchahal, has Been Invited To Present a Keynote Talk at the British Society for Surgery of the Hand (BSSH) at the Autumn Scientific Meeting in Oxford UK on September 9, 2021

ATNF $1.72 (0.00%)

Yahoo! Finance Jul 29, 2021 08:00 AM ET

180 Life Sciences to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference

ATNF $1.72 (0.00%)

Yahoo! Finance Jul 28, 2021 08:15 AM ET

180 Life Sciences Announces Selection of Lead Synthetic CBD Analogue

ATNF $1.72 (0.00%)